ImmunityBio Files 8-K: Regulation FD & Exhibits
Ticker: IBRX · Form: 8-K · Filed: Apr 6, 2026 · CIK: 0001326110
| Field | Detail |
|---|---|
| Company | Immunitybio, Inc. (IBRX) |
| Form Type | 8-K |
| Filed Date | Apr 6, 2026 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulation-fd, filing, exhibit
Related Tickers: IBIO
TL;DR
IBIO filed an 8-K on 4/6/26 - check EX-99.1 for Reg FD info.
AI Summary
ImmunityBio, Inc. filed an 8-K on April 6, 2026, reporting under Regulation FD Disclosure and Financial Statements and Exhibits. The filing includes an exhibit (EX-99.1) which likely contains important information for investors, though the specific details of the disclosure are not provided in the text.
Why It Matters
This 8-K filing indicates ImmunityBio is disclosing material information to the public, which could impact its stock price and investor decisions.
Risk Assessment
Risk Level: medium — 8-K filings can contain significant news, but without knowing the content of the exhibit, the risk level is moderate.
Key Numbers
- 26061 — 8-K Document Size (Size of the main 8-K filing in KB.)
- 20447 — EX-99.1 Document Size (Size of Exhibit 99.1 in KB, likely containing the core disclosure.)
Key Players & Entities
- ImmunityBio, Inc. (company) — Filer of the 8-K
- 0001326110 (company) — CIK number for ImmunityBio, Inc.
- 2026-04-06 (date) — Filing date and period of report
- EX-99.1 (document) — Exhibit containing likely disclosure
FAQ
What specific information is disclosed in Exhibit 99.1?
The provided text does not detail the content of Exhibit 99.1, only that it is part of the 8-K filing.
What is the purpose of a Regulation FD Disclosure?
Regulation FD (Fair Disclosure) requires public companies to disclose material non-public information to the public in a broad and non-exclusionary manner.
What are the business activities of ImmunityBio, Inc. based on the SIC code?
ImmunityBio, Inc. is classified under SIC code 2836, which pertains to Biological Products (excluding diagnostic substances).
When was the filing accepted by the SEC?
The filing was accepted on April 6, 2026, at 08:03:17.
What is the mailing and business address for ImmunityBio, Inc.?
The mailing and business address for ImmunityBio, Inc. is 3530 JOHN HOPKINS COURT, SAN DIEGO CA 92121.
Filing Stats: 539 words · 2 min read · ~2 pages · Grade level 10.7 · Accepted 2026-04-06 08:03:17
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share IBRX The Nasdaq Global Se
Filing Documents
- d70606d8k.htm (8-K) — 25KB
- d70606dex991.htm (EX-99.1) — 20KB
- g70606g0406080032556.jpg (GRAPHIC) — 4KB
- 0001193125-26-142932.txt ( ) — 166KB
- ibrx-20260406.xsd (EX-101.SCH) — 3KB
- ibrx-20260406_lab.xml (EX-101.LAB) — 17KB
- ibrx-20260406_pre.xml (EX-101.PRE) — 11KB
- d70606d8k_htm.xml (XML) — 3KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits . Exhibit Number Description of Exhibit 99.1* Press Release dated April 6, 2026 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). * Furnished herewith.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IMMUNITYBIO, INC. Registrant Date: April 6, 2026 By: /s/ David C. Sachs David C. Sachs Chief Financial Officer